Infliximab is an appropriate second-line therapy in infants with steroid refractory pyoderma gangrenosum

J Eur Acad Dermatol Venereol. 2022 May;36(5):e376-e378. doi: 10.1111/jdv.17921. Epub 2022 Jan 27.

¹ Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
² Department of Pediatrics, Children's Hospital Sankt Augustin, Sankt Augustin, Germany.
³ Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
⁴ Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.
⁵ Department of Dermatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

No abstract available

Publication types